

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 15, No. 11

June 10th, 2016

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- ASCO's updated value framework and opioid therapy policy
- CMS drug reimbursement experiment update
- ACCC MACRA webcast
- CMA's *End of Life Options Act* resources
- ANCO's 2016 Professional Education Program

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on June 24th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960;

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- ☐ Physician Members
- ☐ Nurses & Office Managers
- ☐ Office Staff
- ☐ Colleagues & Representatives

FAX: (415) 472-3961; execdir@anco-online.org.

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

ASCO has published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework defines value as a combination of clinical benefit, side effects, and improvement of patient symptoms or quality of life in the context of cost. Read the updated framework at www.asco.org/value.

ASCO has published a policy statement entitled *Opioid Therapy: Protecting Access to Treatment for Cancer-Related Pain*. ASCO supports efforts to prevent and respond to prescription drug abuse. The full policy statement is available at www.asco.org/sites/new-www.asco.org/files/content-files/advocacy-and-policy/documents/2016_ASCO%20Policy%20Statement%20on%20Opioid%20Therapy.pdf. CMA also has safe prescribing resources for physicians at www.cmanet.org/safe-prescribing.

ASCO supports HR5122, legislation that would halt CMS from implementing the CMS Medicare Part B Drug Reimbursement Experiment and helps to keep the pressure on the *Administration* to withdraw or substantially change the Experiment, and urges the *House* to pass it in a timely manner. Please ask your *Representative* to co-sponsor HR5122 today by visiting cqcengage.com/asco/app/onestep-write-a-letter?0&engagementId=201953.

CMS has issued proposed regulations that would move ahead the two-track physician payment system required under MACRA (see below). The proposed *Quality Payment Program* (QPP) offers providers two options:

- aligning with an advanced Alternative Payment Model (APM) and receiving a 5% annual bonus, or

- being subject to a quality performance score that could result in either increases or decreases in their Medicare reimbursement (i.e., the Merit-Based Incentive Payment System or MIPS).

Over time, providers will be able to move from one track to the other. Comments on the proposed rule are due June 27th; the final rule is slated to be released in the Fall of 2016. Read CMS's press release at www.hhs.gov/about/news/2016/04/27/administration-takes-first-step-implement-legislation-modernizing-how-medicare-pays-physicians.html. Read Bobbie Buell's analysis of the MACRA proposal at www.anco-online.org/BBMacraAnalysis.pdf. Join ACCC on June 14th for an interactive webinar on MACRA. Go to attendeegotowebinar.com/register/2308644939852908546 for more information and to register.

MACRA encourages the development of alternatives to the current Medicare fee-for-service payment system as a means to achieve higher quality and more affordable care. ASCO believes that its *Patient-Centered Oncology Payment* (PCOP) model meets MACRA's definition of an alternative payment model (APM) and will actively advance PCOP as a certified APM. ASCO is offering practices a unique opportunity to test PCOP and will provide tools and assistance in modeling data to help practices be successful. To learn more about PCOP, please go to www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform.

CMS has released a new transmittal and *Medlearn Matters* regarding billing for drug waste packaged in a single dose vial. Starting July 1st, Medicare contractors will require the use of modifier JW to identify unused drugs or biologicals from single use vials or single use packages that are appropriately discarded. This modifier, billed on a separate line, will provide payment for the amount of discarded drug or biological. The only exception to the above is when the J-code is larger than the drug plus the waste. In addition, documentation in the record must reflect the drug given plus the amount of drug wasted; every effort must be made to use drugs "in such a way that they can use drugs or biologicals most efficiently, in a clinically appropriate manner" (i.e., drugs should not be wasted if there are other patients that can use the waste or if there is a

smaller vial size); and, this guidance does not apply to multi-dose vials because Medicare does not pay for wasted drug units in this scenario.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

The *California Medical Association* (CMA) has released guidance for prescribing lethal doses of medication under California's new physician-assisted death law (ABX2-15). CMA's *The California End of Life Option Act* is available at www.cmanet.org/resource-library/detail/?item=the-california-end-of-life-option-act. The *End of Life Option Act* became law on June 9th. The CMA guidance details the legal and medical steps physicians must take before prescribing life-ending medications and physicians' legal rights to participate or opt out based on their moral or religious beliefs. The guidelines are written in a Q&A format and provide detailed information about the new law.

Under California law, all individuals practicing in California who possess both a state regulatory Board license authorized to prescribe, dispense, furnish, or order controlled substances and a *Drug Enforcement Administration Controlled Substance Registration Certificate* (DEA Certificate) must register for the *Controlled Substance Utilization Review and Evaluation System* (CURES) by July 1st. The *California Medical Association* (CMA) recently co-hosted a webinar with the *Department of Justice* (DOJ) to help physicians navigate the CURES 2.0 registration process. The webinar is now available on demand at www.cmanet.org/resource-library/detail/?item=cures-20-navigating-the-states-new0&r_search=&r_page=&return_to=list.

On July 1st, a new law (SB137) will take effect that requires health plans to ensure that physician directories are accurate and up-to-date. The new law also requires physicians to do their part in keeping this information up-to-date. Specifically, the law requires providers to notify payors within five business days if they are no longer accepting

new patients or, alternatively, if they were previously not accepting new patients and are now open to new patients. SB137 also requires physicians to respond to plan and insurer notifications regarding the accuracy of their provider directory information, either by confirming the information is correct or by updating demographic information as appropriate. Contact CMA's reimbursement help line at (888) 401-5911 or economicservices@cmanet.org for more information.

Forthcoming CMA webinars include:

- MACRA and the Quality Payment Program: An Update on the Recent Proposed Rule (June 15)

Contact CMA's member help center at (800) 786-4262 or memberservice@cmanet.org for more information. Register online at www.cmanet.org/events.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The June 2016 edition includes:

- UnitedHealthcare to exit Covered California at the end of 2016
- UnitedHealthcare adopting protocol for submission of clinical data
- Reminder: CMS meaningful use hardship exception deadline is July 1
- Noridian begins deactivation of providers who failed to revalidate
- The End of Life Option Act takes effective on June 9: What you need to know
- CMA publishes tip sheet on Medicare quality reporting programs
- Maintaining your Medicare opt-out status
- The Coding Corner: Annual updates resume for ICD-10; Changes coming October 1

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the **Jurisdiction E (JE) Medicare Administrative Contractor (MAC)**. Jurisdiction E includes California. Regularly review postings at the **Noridian/JEMAC** website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—ICD-10 Resources: Clinical Concepts Series; 2016 PQRS GPRO Registration Open through June 30
- *Claims, Pricers, and Codes*—July 2016 Average Sales Price Files Available; 2017 ICD-10-PCS Updates Available
- *Events*—Physician Compare Initiative Call-June 16; Quality Measures and the IMPACT Act Call-July 7
- *Publications*—Updated Information on the IVIG Demonstration MLN Matters Article-New
- IUD (Hormone-Eluting) for Endometrial Hyperplasia-CPT 58999-Revised
- MolDX: Molecular RBC Phenotyping-R1
- MPFSDB-July 2016 Quarterly Update CR9633
- Claim Status Category and Claim Status Codes Updates CR9550
- There is Still Time to Rate Us
- JW Modifier: Drug Amount Discarded/Not Administered to any Patient-Revised CR9603

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming Noridian/JEMAC meetings/workshops include:

- Clinical Lab and CERT Workshop (June 15)
- Ordered, Referred and Prescribed Services Workshop (June 16)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

Subscribe today to receive the DHCS/Medi-Cal Subscription Service (MCSS) via e-mail. The MCSS is a free service that can help keep you up-to-date on the latest DHCS/MediCal news. Go to the MCSS Subscriber Form (files.medi-cal.ca.gov/pubsdoco/mcss/mcss.asp) to subscribe.

A list of DHCS/MediCal webinars is at files.medi-cal.ca.gov/pubsdoco/newsroom/newsroom_23149.asp?utm_source=iContact&utm_medium=email&utm_campaign=Medi-Cal%20NewsFlash&utm_content=23149.

DHCS/MediCal is continuing the development of the PAVE system that will improve the way providers do business with DHCS's *Provider Enrollment Division* (PED) and simplify and expedite the enrollment experience. For more information about the PAVE project and how to get involved, please visit www.dhcs.ca.gov/provgovpart/Pages/PAVE.aspx.

DHCS/MediCal is continuing to develop policy to implement SB1004 that requires DHCS to establish standards and provide technical assistance for DHCS/MediCal managed care plans for the delivery of palliative care services. Please visit www.dhcs.ca.gov/provgovpart/Pages/Palliative-Care-and-SB-1004.aspx to view the initial concept paper, stakeholder feedback, and materials from previous stakeholder meetings.

Anthem Blue Cross Network Update (June 2016) is now available online at www.anthem.com/ca/provider/f5/s3/t3/pw_e246160.pdf and includes articles entitled Health Insurance Exchange Updates, Update Regarding Specialty Pharmacy Program Expansion, Contracted Provider Claim Escalation Process, and Guidelines and Quality Programs.

UnitedHealthcare's Network Bulletin (June 2016) is now available online at unitedhealthcareonline.com > Quick Links > Network Bulletin and includes articles entitled UnitedHealthcare Adds RadSite and The Joint Commission as Imaging Accreditation Organizations—Effective July 1, 2016; and, Outreach Efforts to Begin July 1 to Support Care Providers with Continued Adoption of Clinical Data and Submission Protocol.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2016

Professional Education Meeting

ANCO will host its 2016 professional education meeting on August 3rd at *The Claremont Resort*. An announcement with the agenda and faculty will be distributed in early June. The agenda includes *MACRA—What It Is and How Oncology Practices Can Prepare; Managing Oncology within Medicare; California's End of Life Option Act; and, An ANCO Practice Atlas—Who We Are, What We are Doing in Our Practices, and How This Compares to Other Oncology Practices*. The faculty will be Sybil Green, JD, RPh, *Director, Coverage and Reimbursement, ASCO*; Arthur Lurvey, MD, FACP, FACE, *Medicare Contractor Medical Director, Noridian/JEMAC*; Shirley Otis-Green, MSW, ACSW, LCSW, OSW-C, *Clinical Director of Consulting Services, Coalition for Compassionate Care of California*; and, Elaine L. Towle, CMPE, *Director, Analysis and Consulting Services, Clinical Affairs Department, ASCO*. Download the meeting announcement and registration form at www.anco-online.org/ProfEduc2016.pdf.

ASCO's Best of ASCO

ASCO's *Best of ASCO* takes place in San Diego on August 12-13th. Visit boa.asco.org for more information and to register.

SAVE THE DATE

ANCO's ASCO Highlights 2016

ANCO's *ASCO Highlights 2016* will take place on Saturday, August 27th at *The Claremont Resort* in Oakland. Faculty from *Stanford University*, the *University of California, Davis*, and the *University of California, San Francisco* will summarize the research and treatment advances reported at *ASCO's Annual Meeting*. A meeting announcement and registration form will be distributed in late June.

Additional Education Meetings

Other meetings of possible interest to ANCO member practices are:

June 14th

Highlights from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting (Part II of Your Guide to the Latest Cancer Research and Treatment)

CancerCare

Connect Education Workshop

June 16th

Update on Chronic Lymphocytic Leukemia (CLL)

CancerCare

Connect Education Workshop

June 17th

Medical Update on Acute Myelogenous Leukemia (AML)

CancerCare

Connect Education Workshop

June 28th

Step Therapy and You: How Step Therapy Policies Affect Patient Access to Treatment

California Partnership for Access to Treatment

Sacramento

(<https://www.eventbrite.com/e/step-therapy-you-tickets-25659331752>)

June 28th

Transplantation as a Treatment Option for Blood Cancers

CancerCare

Connect Education Workshop

June 29th

Precision Medicine in Cancer Treatment

CancerCare

Connect Education Workshop

June 30th

Update on Glioblastoma

CancerCare

Connect Education Workshop

July 20th

Triple Negative Breast Cancer and African American Women

CancerCare

Connect Education Workshop

August 4-6th

17th Annual International Lung Cancer Congress Physicians' Education Resource

Huntington Beach

(www.gotoper.com/conferences/ilc/meetings/17th-International-Lung-Cancer-Congress)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors teleconference is scheduled for June 22nd**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

ANCO is proud to report that **Primo Lara, Jr., M.D.**, has been appointed the interim director at the *UC Davis Comprehensive Cancer Center*.

Nominations for the ASCO Annual Election are now open and will be accepted through June 12th. The open positions are *Board of Directors (President-Elect, Designated Community Oncologist, Designated Medical Oncologist, Undesignated Specialty Oncologist)*, and *Nominating Committee (Undesignated Specialty Oncologist)*. Go to www.asco.org/about-asco/asco-overview/asco-election for more information and to submit a nomination.

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group (TPMG)* will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks

Annadel Medical Group/St Joseph's Heritage Healthcare, California Cancer Associates for Research and Excellence, Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Pacific Cancer Care, Palo Alto Medical Foundation, and Valley Medical Oncology Consultants for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Alexion Pharmaceuticals • AMGEN
ARIAD Pharmaceuticals • Astellas Oncology
AstraZeneca • Bayer Healthcare Pharmaceuticals
Biodesix • Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Dendreon • Eisai • Foundation Medicine
Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Lilly Oncology • Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Onyx Pharmaceuticals
Pfizer Oncology • Pharmacyclis
Prometheus Therapeutics & Diagnostics
Sandoz Biopharmaceuticals • Sanofi Genzyme
Sargas Pharmaceutical Adherence
& Compliance (SPAC) International*

*Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *AbbVie, ARIAD Pharmaceuticals, Biodesix, Clovis Oncology, GenPath Oncology, Guardant Health, Heron Therapeutics, Infinity Pharmaceuticals, Ipsen Pharmaceuticals, Jazz Pharmaceuticals, Merrimack Pharmaceuticals, Prometheus Therapeutics & Diagnostics, Sandoz Biopharmaceuticals, Taiho Oncology, and Tesaro* as new Corporate Members for 2016. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AMGEN informs ANCO that the *United States Food and Drug Administration* has issued a Risk Evaluation and Mitigation Strategy (REMS) letter for Prolia to address the potential risks of hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, serious infections, and dermatologic infections. More information is available at www.proliahcp.com/risk-evaluation-mitigation-strategy/.

Seattle Genetics is hosting a webcast entitled *Optimal Clinical Strategies for the Treatment of Relapsed Hodgkin's Lymphoma* with Craig Moskowitz, M.D., *Memorial Sloan Kettering Cancer Center*, on June 14th at 10AM. To register for this program, visit www.optumhealtheducation.com/oncology/rhl-2016-live?utm_source=SubscriberMail&utm_medium=email&utm_campaign=6.14.16%20rhl%20invite&utm_term=&utm_content=136a6447527d4163b80df1a8d1df0917.

Teva Oncology informs ANCO that CMS has made a preliminary decision to assign J-Code J9033 to Bendeka and some payers have updated their systems to reflect the change from J9999. You must adhere to specific payor recommendations to determine which code to use for Bendeka. CMS's final decision is expected in the fourth quarter. If a unique J code is recommended at that time for Bendeka, the effective date would be January 1st, 2017.

Clinical Trial News

ASCO's *Research Community Forum* (formerly the *Community Research Forum*) is expanding to have a greater impact on research sites from all

types of research settings. The *Forum* is inviting researchers and staff from all types of sites to participate in this unique venue with the aim to advance cancer research and support research program management. The *Forum's* annual meeting takes place at ASCO on September 25-26th. Please visit www.asco.org/research-community-forum to learn more.

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase III International Randomized Study of Transarterial Chemoembolization (TACE) versus Stereotactic Body Radiotherapy (SBRT)/Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma after Initial TACE. Principal Investigator: Daniel Chang, MD; Contact: Rachel Freiberg, (650) 725-0438, rachelf@stanford.edu
- A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors [NET0012; NCT01525082]. Principal Investigator: Pamela Kunz, MD; Contact: Ativ Zomet, (650) 736-0697, azomet@stanford.edu
- Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma [NCT02110563]. Principal Investigator: Pamela Kunz, MD; Contact: Ativ Zomet, (650) 736-0697; azomet@stanford.edu
- A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors [NCT02576431]. Principal Investigator: Shivaani Kummar, MD, PhD; Contact: Kristine M. McGlennen, (650) 723-3589; kmcglenn@stanford.edu
- A Phase II Study of Epacadostat (INCB024360) with Pembrolizumab (MK-3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies. Principal Investigator: Pamela Kunz, MD, PhD; Contact: Ativ Zomet, (650) 736-0697; azomet@stanford.edu

UC Davis brings the following clinical trial (not previously listed or changed) to the attention of the ANCO membership:

- A Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy (UCDCC#256/NCT02553941). Principal

Investigator: Brian Jonas, M.D., Ph.D.; Contact:
Christina Romo, (916) 734-1455

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects with Advanced Malignancies (CC#15958). Contact: Brittany Bianchi, (415) 885-3725, brittany.bianchi@ucsf.edu
- A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma who Progressed on or Were Intolerant to First-Line Systemic Therapy (CC#16456). Contact: Anna Crosetti, (415) 514-8101, anna.crosetti@ucsf.edu
- Protocol I3O-MC-JSBF Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer (CC#16457). Contact: Malori Mindo, (415) 502-6313, malori.mindo@ucsf.edu
- A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CC#13455). Contact: Malori Mindo, (415) 502-6313, malori.mindo@ucsf.edu
- Phase I Study to Evaluate the Safety of Neratinib in Combination with Paclitaxel, Trastuzumab and Pertuzumab in Women and Men with Advanced or Metastatic HER2+ Solid Tumors (CC#149517). Contact: Kathleen (Katie) Comerford, (415) 514-6674, kathleen.comerford@ucsf.edu
- Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies. Contact: Thomas Hope, thomas.hope@ucsf.edu
- A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Dose, and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors (CC#15957). Contact: Brittany Bianchi, (415) 885-3725; brittany.bianchi@ucsf.edu
- Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma Who Have Had Disease Progression on Sorafenib or Are Not Eligible to Receive Sorafenib (CC#11452). Contact: Anna Crosetti, (415) 514-8101; anna.crosetti@ucsf.edu
- Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors (CC#16954). Contact: Ilaria Mastroserio, (415) 514-6245; ilaria.mastroserio@ucsf.edu
- An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-like Protein 3-Expressing Advanced Solid Tumors (CC#16955). Contact: Ilaria Mastroserio, (415) 514-6245; ilaria.mastroserio@ucsf.edu

• A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab + Pembrolizumab and Demcizumab + Pembrolizumab, Pemetrexed, and Carboplatin in Patients with Locally Advanced or Metastatic Solid Tumors (CC#159521). Contact: Ilaria Mastroserio, (415) 514-6245; ilaria.mastroserio@ucsf.edu

Publications, Resources, Services, & Surveys

ANCO and MOASC have partnered with SullivanLuallin Group to offer your practice the opportunity to participate in an Oncology-based Patient Satisfaction Survey. The Survey is designed to assess your organization's performance in key areas associated with the ACO and PQRS CAPHS Surveys. SullivanLuallin Group's eSurv: Online Patient Satisfaction Survey platform allows you to efficiently and cost-effectively capture how your patients feel about your systems, services, and performance. Download more information and an enrollment form at www.anco-online.org/PtSurvey2016.pdf.

ANCO and MOASC are jointly conducting a 2016 staff salary survey. The survey was e-mail/FAXed to all members in mid-May and is available online at www.anco-online.org/salsrvy.html. A \$50 Visa gift card for respondents is included in this year's survey. Return your completed survey no later than September 30th; results will be analyzed and reported in 4Q2016.

ASCO's CancerLinQ has launched a new website with expanded information and features for users to meet the needs of patients, practices, donors, researchers, and the larger oncology community. Visit www.CancerLinQ.org to learn more.

ANCO member practices Diablo Valley Oncology & Hematology Medical Group, EPIC Care-Partners in Cancer Care, and Marin Cancer Care are amongst the 58 oncology practices from around the country that have signed agreements to begin implementing CancerLinQ.

ASCO's Quality Training Program is currently accepting applications through June 15th. The Program is designed to train oncology health care providers to investigate and implement data-driven quality improvement and manage clinical and non-clinical processes and outcomes. For more information, visit www.institutequality.org/how-apply.

CMS has approved ASCO's Quality Oncology Practice Initiative (QOPI) as a qualified clinical data registry (QCDR), a pathway for oncologists

to meet the agency's current quality reporting requirements. Oncology practices registered with QOPI will have the opportunity to fulfill CMS's PQRS or QCDR reporting requirements through QOPI. QOPI is designed to promote excellence in cancer care by helping oncologists create a culture of self-examination and improvement. ASCO offers the *QOPI Certification Program* to recognize QOPI participants who achieve rigorous standards for cancer care. The *QOPI Certification* designation can be used by certified practices to demonstrate an advanced commitment to quality and are eligible to receive a discount of up to 10% on medical malpractice rates from *The Doctors Company*, the nation's largest physician-owned medical malpractice insurer. Go to www.institutequality.org/qopi-qcp for more information.

ACCC's online Oncology Drug Database provides quick access to information on oncology drug coding, billing, and reimbursement at www.accc-cancer.org/drugdatabase/.

ACCC's enhanced set of Financial Advocacy Network resources are at www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp. This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

ACCC's 2016 Patient Assistance and Reimbursement Guide is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. New for 2016 are tips for optimizing co-pay assistance programs and new financial advocate skills for the new healthcare environment. Visit www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2016.pdf to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org. **ASH also has a webpage (at www.hematology.org/Clinicians/Drugs/Programs/) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs.** And, at NCCN's Reimbursement Resource

Room (www.nccn.org/reimbursement_resource_room/default.asp) you can select a cancer diagnosis or supportive care indication and learn about reimbursement help and services available to you. Finally, *assistPoint* is your **website for complimentary one-stop cancer Patient Assistance.** You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for 113 cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more.

The National Comprehensive Cancer Network (NCCN) has published the NCCN Imaging Appropriate Use Criteria to support clinical decision-making around the use of imaging in patients with cancer, helping to assure needed and useful imaging while potentially saving patients from unneeded or inappropriate imaging. For more information, go to www.nccn.org/professionals/imaging/default.aspx. **NCCN has updated their Clinical Practice Guidelines in Oncology and/or Drugs & Biologics Compendium** for antiemesis (V2.2016) and prostate cancer (V3.2016).

Individual Membership Dues for 2016

Final notices of membership renewal for 2016 were mailed in early May. If you have not yet done so, then please return your 2016 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.